Elekta AB 2025 AR2
The report highlights Elekta's fiscal year 2024/25, marked by the successful clinical launch of the Elekta Evo CT-Linac and additions to the Elekta ONE software suite. The company achieved its target of providing cancer care access to over 300 million people in underserved markets. Financially, net sales reached SEK 18,016 million, though results were impacted by a non-cash impairment of SEK 1,094 million primarily related to discontinued R&D projects. On the environmental front, Elekta reduced its total greenhouse gas emissions across all scopes by 9 percent and improved its CDP Climate Change score to a B.
Company: Elekta AB
Sector: Health Care
Country: Sweden
Year: 2025
Type: AR2
Pages: 129
Elekta AB
Annual Report
The report highlights Elekta's fiscal year 2024/25, marked by the successful clinical launch of the Elekta Evo CT-Linac and additions to the Elekta ONE software suite. The company achieved its target of providing cancer care access to over 300 million people in underserved markets. Financially, net sales reached SEK 18,016 million, though results were impacted by a non-cash impairment of SEK 1,094 million primarily related to discontinued R&D projects. On the environmental front, Elekta reduced its total greenhouse gas emissions across all scopes by 9 percent and improved its CDP Climate Change score to a B.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
May 1, 2024 - Apr 30, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Total Waste
Women on Board
Women in Management
Employees